Drug duo aims to starve thyroid tumors
NCT ID NCT01141309
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining two oral drugs—sorafenib and everolimus—can shrink tumors or slow disease in people with advanced thyroid cancer that cannot be removed by surgery. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps cancer cells grow. The study also looks for genetic markers that might predict who benefits most from this combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of two oral drugs: sorafenib and everolimus
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced thyroid cancer that cannot be surgically removed.
- What could go wrong
- This is a small, early-phase trial, so the combination may not work better than existing treatments and could cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple tool may help thyroid cancer patients avoid treatment regret
- Could your DNA predict thyroid cancer after radiation?
- Smartphone app could ease neck pain after thyroid surgery
- New imaging tracer could spot hidden cancers and fibrosis in one scan
- Cancer drug pralsetinib may change how the body processes other medications
- Sharper radiation boost aims to tackle head and neck cancers that return